Advanced Filters
noise

Bowling Green, Kentucky Clinical Trials

A listing of Bowling Green, Kentucky clinical trials actively recruiting patient volunteers.

Found 34 clinical trials
O Oruka Investigative Site

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

18 years of age All Phase 2
K Kay Douthitt

OASIS: Peer Support for T2DM in Appalachia (Peer Participant)

The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? If effective, which facets of the peer …

55 years of age All Phase N/A
K Kay Douthitt

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

The goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. The main questions it aims to answer are: Are peer coaching models effective at promoting Type 2 Diabetes Mellitus self-management? If effective, which facets of the peer …

55 years of age All Phase N/A

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

12 - 75 years of age All Phase 1

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

This study will test a study drug called cemiplimab to see if it can help treat early-stage cutaneous squamous cell carcinoma (CSCC), a type of skin cancer. Cemiplimab works by helping the immune system to kill cancer cells. It binds to a protein called programmed cell death-1 (PD-1) on the …

18 years of age All Phase 3
M Mohammadreza Heidari

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when …

18 years of age All Phase 3
M Melinda Joyce, PharmD, FAPhA, FACHE

IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches

The goal of this clinical trial is to learn which iron treatment works better for adults with congestive heart failure and low iron levels: intravenous (IV) iron given through a vein or oral (PO) iron taken by mouth. Participants must have heart failure with reduced ejection fraction (HFrEF) or preserved …

18 - 100 years of age All Phase 4
G Genesis Guzman

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

18 years of age All Phase 2
P Principal Investigator

A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

18 - 68 years of age All Phase 2

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.

18 years of age All Phase 4

Simplify language using AI